General principles of pharmaceutical solid polymorphism:: a supramolecular perspective

被引:345
作者
Rodríguez-Spong, B
Price, CP
Jayasankar, A
Matzger, AJ
Rodriguez-Hornedo, N
机构
[1] Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA
关键词
supramolecular isomers; supramolecular pharmaceutics; crystallization; crystal engineering; cocrystals; solvates; molecular dispersions;
D O I
10.1016/j.addr.2003.10.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The diversity of solid-state forms that an active pharmaceutical ingredient (API) may attain relies on the repertoire of non-covalent interactions and molecular assemblies, the range of order, and the balance between entropy and enthalpy that defines the free energy landscape. It is recognized that crystallization is associated with molecular recognition events that lead to self-assembly, and that pharmaceutical function and thermodynamic stability can be altered with a slight change in the interacting molecules or their molecular network motifs. Our current understanding of pharmaceutical solids in terms of molecular recognition and complementarity provides new insights into the design and function of single and fully miscible, multiple-component solids with varying degrees of order, from amorphous to crystalline states, and in this way is leading the path to supramolecular phannaceutics. This review describes pharmaceutical solids in terms of supramolecular chemistry and crystal engineering concepts, and discusses the events that control crystallization and solid phase transformations. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:241 / 274
页数:34
相关论文
共 191 条
[1]   Do polymorphic compounds make good cocrystallizing agents?: A structural case study that demonstrates the importance of synthon flexibility [J].
Aakeröy, CB ;
Beatty, AM ;
Helfrich, BA ;
Nieuwenhuyzen, M .
CRYSTAL GROWTH & DESIGN, 2003, 3 (02) :159-165
[2]   Preparation and characterization of Furosemide-Eudragit controlled release systems [J].
Aceves, JM ;
Cruz, R ;
Hernandez, E .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 195 (1-2) :45-53
[3]   1:1 complex of octadecanoic acid and 3-pyridinecarboxamide [J].
Amai, M ;
Endo, T ;
Nagase, H ;
Ueda, H ;
Nakagaki, M .
ACTA CRYSTALLOGRAPHICA SECTION C-CRYSTAL STRUCTURE COMMUNICATIONS, 1998, 54 :1367-1369
[4]  
ANDO H, 1986, INT J PHARMACEUT, V34, P153
[5]   Crystal nucleation and growth of indomethacin polymorphs from the amorphous state [J].
Andronis, V ;
Zografi, G .
JOURNAL OF NON-CRYSTALLINE SOLIDS, 2000, 271 (03) :236-248
[6]  
[Anonymous], 2003, CRYSTAL DESIGN STRUC
[7]  
[Anonymous], 1992, CRYSTALLIZATION
[8]   Laser Raman spectroscopic analysis of polymorphic forms in microliter fluid volumes [J].
Anquetil, PA ;
Brenan, CJH ;
Marcolli, C ;
Hunter, IW .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (01) :149-160
[9]  
AZIZOV MA, 1954, DOKL AKAD NAUK SSSR, V1, P33
[10]   CONFORMATIONAL POLYMORPHISM .6. THE CRYSTAL AND MOLECULAR-STRUCTURES OF FORM-II, FORM-III, AND FORM-V OF 4-AMINO-N-2-PYRIDINYLBENZENESULFONAMIDE (SULFAPYRIDINE) [J].
BAR, I ;
BERNSTEIN, J .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1985, 74 (03) :255-263